What are the recommended vaccinations for a 45-year-old patient with end-stage renal disease on dialysis?

Vaccination Recommendations for 45-Year-Old ESRD Patient on Dialysis

A 45-year-old patient with end-stage renal disease on dialysis should receive hepatitis B vaccine (high-dose series), annual influenza vaccine (preferably high-dose or enhanced formulation), pneumococcal vaccines (PCV13/PCV15/PCV20 followed by PPSV23), recombinant zoster vaccine (Shingrix), COVID-19 vaccine, and age-appropriate tetanus/diphtheria boosters. 1, 2

Core Vaccination Algorithm

1. Hepatitis B Vaccination (Highest Priority)

• Administer high-dose HBV vaccine series if anti-HBs negative 1, 2
• Dosing: 40 μg at 0,1,2, and 6 months (Engerix-B) OR 40 μg at 0,1, and 6 months (Recombivax HB) 2
• Test anti-HBs 1-2 months after completion; if <10 mIU/mL, administer second complete series 1, 2
• For responders, check antibody levels annually and give booster if <10 mIU/mL 3
• Critical caveat: Patients respond better if vaccinated before dialysis initiation, but vaccination after dialysis start remains essential 4

Alternative option: Heplisav-B vaccine (newer formulation) may be considered 5

2. Influenza Vaccination (Annual)

• Administer high-dose or enhanced influenza vaccine annually 2, 6
• High-dose vaccine provides modestly increased protection versus standard-dose (relative vaccine effectiveness ~5-18% for influenza-related outcomes) 6
• Live attenuated influenza vaccine is contraindicated in dialysis patients 2
• Timing: Give during flu season; can be administered at any dialysis session

3. Pneumococcal Vaccination

Sequential vaccination strategy 1, 2:

• Give PCV13 first (or newer PCV15/PCV20 if available) 5
• Follow with PPSV23 at least 8 weeks later 2
• If PPSV23 given first, wait 1 year before PCV13 2
• Administer second dose of PPSV23 five years after first dose 1, 2
• This patient requires 2 lifetime doses of PPSV23, 5 years apart 1

4. Recombinant Zoster Vaccine (Shingrix)

• Administer 2 doses of RZV (Shingrix) 2-6 months apart 2
• This is the preferred vaccine over live zoster vaccine (Zostavax), which is contraindicated 2
• Recommended for all dialysis patients ≥50 years; this 45-year-old patient should receive it now as they meet age criteria in some guidelines

5. COVID-19 Vaccination

• Administer per current CDC recommendations 5
• Dialysis facilities can administer these vaccines 5

6. Tetanus/Diphtheria

• Follow standard adult immunization schedule 1, 7
• Ensure up-to-date with Td or Tdap boosters every 10 years

7. Additional Considerations

• Hepatitis A: Recommended if chronic liver disease present or transplant candidate 1, 3
• HPV vaccine: If not previously vaccinated and ≤26 years (not applicable to this 45-year-old) 1
• Respiratory Syncytial Virus (RSV): Newly available; role in dialysis facilities uncertain 5

Critical Implementation Points

Timing matters: Vaccination should ideally occur before dialysis initiation when immune response is better 4, 8. However, since this patient is already on dialysis, proceed immediately with the vaccination schedule.

Prior nephrology consultation strongly predicts vaccine uptake (72.1% vs 21.9% for HBV, p<0.001) 8. The fact that this patient is established on dialysis suggests nephrology involvement, which should facilitate vaccination.

Common pitfall: Only 47.7% of dialysis patients complete HBV vaccination, and 55.3% remain completely unvaccinated 8. Do not miss this opportunity—integrate vaccination into routine dialysis care.

Reduced immune response: Dialysis patients have impaired vaccine responses 4, 9. This necessitates:

• Higher HBV vaccine doses (40 μg vs 20 μg standard)
• Post-vaccination antibody testing for HBV
• Potential need for repeat vaccination series

Vaccination coverage gaps are substantial: Influenza vaccination rates are ~71%, but pneumococcal coverage is only ~53% within 3 years of dialysis initiation 10. Pneumococcal vaccination significantly reduces pneumonia-related hospitalizations (2.2% vs 7.5%, p=0.032) 11.

Evidence Quality Notes

The 2013 IDSA guideline 1 provides the foundational framework (strong recommendations, moderate evidence), while the 2020 AJKD core curriculum 2 offers practical implementation guidance specific to dialysis units. The 2024 Kidney Medicine review 5 updates recommendations with newer vaccines (PCV15/PCV20, Heplisav-B, RSV). The 2026 JASN study 6 provides the highest-quality recent evidence supporting enhanced influenza vaccine formulations in this population.